argenx NV ADR (ARGX)vsZai Lab Ltd (ZLAB)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
ZLAB
Zai Lab Ltd
$18.29
+4.69%
HEALTHCARE · Cap: $2.02B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 821% more annual revenue ($4.24B vs $460.16M). ARGX leads profitability with a 30.5% profit margin vs -38.2%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
ZLAB
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Intrinsic value data unavailable for ZLAB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Reasonable price relative to book value
17.0% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% earnings growth
Weak financial health signals
ROE of -22.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : ZLAB
The strongest argument for ZLAB centers on Price/Book, Revenue Growth. Revenue growth of 17.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : ZLAB
The primary concerns for ZLAB are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ZLAB carries more volatility with a beta of 0.88 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (63/100 vs 30/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Zai Lab Ltd
HEALTHCARE · BIOTECHNOLOGY · China
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?